The comparison of EGFR-TKI failure modes and subsequent management between exon 19 deletion and exon 21 L858R mutation in advanced non-small-cell lung cancer-Reference-Cited by-同舟云学术

The comparison of EGFR-TKI failure modes and subsequent management between exon 19 deletion and exon 21 L858R mutation in advanced non-small-cell lung cancer

Published:2017 Issue:10 Volume:8 Page:1865-1871
ISSN:1837-9664
Container-title:Journal of Cancer
language:en
Short-container-title:J. Cancer

Author:

Zhang Yaxiong,Chen Gang,Chen Xi,Fang Wenfeng,Gao Fei,Yang Yunpeng,Zhao Yuanyuan,Ma Yuxiang,Hong Shaodong,Zhang Zhonghan,Miao Siyu,Wu Manli,Huang Xiaodan,Luo Youli,Zhou Cong,Gong Run,Huang Yan,Chen Likun,Zhou Ningning,Zhao Hongyun,Zhang Li

Publisher

Ivyspring International Publisher

Subject

Oncology

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Benefit assessment of extended dosing in cancer patients after their withdrawal from clinical trials;Frontiers in Pharmacology;2023-12-15

2. An exploration of the clinical progression models of osimertinib in the treatment of advanced EGFR-mutant non-small cell lung cancer;Translational Lung Cancer Research;2022-05

3. ΔCT Value of Amplified Refractory Mutation System Predicts Efficacy of EGFR-TKIs in Advanced Non–Small-Cell Lung Cancer: A Multi-Center Retrospective Study;Frontiers in Molecular Biosciences;2021-10-08

4. EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients;Translational Lung Cancer Research;2020-06

5. mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase/AKT/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma;Journal of Cancer Research and Therapeutics;2019